Abstract
Human immunodeficiency virus (HIV) persists in lymph nodes and lymphoid tissues even during aggressive drug treatment, likely due to insufficient drug concentrations at this site. Therefore, to eliminate this residual virus, methods that enhance lymph node drug concentrations are currently being evaluated. Although enhanced drug concentrations in tissue have been achieved with drug-associated lipid nanoparticles, targeting these particles to CD4+ cells may provide specific delivery of drug to HIV target cells and further enhance drug efficacy. We have evaluated four candidate peptides with reported binding specificity to CD4 for anchoring on lipid nanoparticle preparations previously shown to localize in lymph nodes. Terminal cysteine containing candidate peptides were conjugated to lipid nanoparticles through maleimide-linked phopholipids for targeting to CD4 cells. Using fluorescently labeled lipid nanoparticle binding to cells with varying degree of CD4 expression (CEMx174, Molt-4, Jurkat, and Ramos), we indentified two peptide sequences that provided CD4 selectivity to nanoparticles. These two peptide candidates on lipid nanoparticles bound to cells corresponding to the degree of CD4 expression and in a peptide dose dependent manner. Further, binding of these targeted lipid nanoparticles was CD4 specific, as pre-exposure of CD4+ cells to anti-CD4 antibodies or free peptides inhibited the binding interactions. These results indicate targeting of lipid nanoparticles for specific binding to CD4 can be accomplished by tagging CD4 binding peptides with peptides, and these results provide a basis for further evaluation of this targeted delivery system to enhance antiviral drug delivery to CD4+ HIV host cells, particularly those in lymph nodes and lymphoid tissues.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
WHO (2009). Global summary of the AIDS epidemic [11/11/10]. Available from: http://www.who.int/hiv/data/2009_global_summary.png.
Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med. 1998;338(13):853–60.
Roge BT, Barfod TS, Kirk O, Katzenstein TL, Obel N, Nielsen H, et al. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study. HIV Med. 2004;5(5):344–51.
Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278(5341):1291–5.
Wong JK, Gunthard HF, Havlir DV, Zhang ZQ, Haase AT, Ignacio CC, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci USA. 1997;94(23):12574–9.
Ruiz L, van Lunzen J, Arno A, Stellbrink HJ, Schneider C, Rull M, et al. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS. 1999;13(1):F1–8.
Brodie SJ, Patterson BK, Lewinsohn DA, Diem K, Spach D, Greenberg PD, et al. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest. 2000;105(10):1407–17.
Kinman L, Brodie SJ, Tsai CC, Bui T, Larsen K, Schmidt A, et al. Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques. J Acquir Immune Defic Syndr. 2003;34(4):387–97.
Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2003;47(1):238–43.
Gunaseelan S, Gunaseelan K, Deshmukh M, Zhang X, Sinko PJ. Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs. Adv Drug Deliv Rev. 2010;62(4–5):518–31.
Kinman L, Bui T, Larsen K, Tsai CC, Anderson D, Morton WR, et al. Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. J Acquir Immune Defic Syndr. 2006;42(2):155–61.
Choi SU, Bui T, Ho RJ. pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to entrap a solute. J Pharm Sci. 2008;97(2):931–43.
Tedla N, Dwyer J, Truskett P, Taub D, Wakefield D, Lloyd A. Phenotypic and functional characterization of lymphocytes derived from normal and HIV-1-infected human lymph nodes. Clin Exp Immunol. 1999;117(1):92–9.
Duzgunes N, Pretzer E, Simoes S, Slepushkin V, Konopka K, Flasher D, et al. Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells. Mol Membr Biol. 1999;16(1):111–8.
Pollock S, Dwek RA, Burton DR, Zitzmann N. N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery. AIDS. 2008;22(15):1961–9.
Slepushkin VA, Salem II, Andreev SM, Dazin P, Duzgunes N. Targeting of liposomes to HIV-1-infected cells by peptides derived from the CD4 receptor. Biochem Biophys Res Commun. 1996;227(3):827–33.
Clayton R, Ohagen A, Nicol F, Del Vecchio AM, Jonckers TH, Goethals O, et al. Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes. Antiviral Res. 2009;84(2):142–9.
Gagne JF, Desormeaux A, Perron S, Tremblay MJ, Bergeron MG. Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim Biophys Acta. 2002;1558(2):198–210.
Desormeaux A, Bergeron MG. Lymphoid tissue targeting of anti-HIV drugs using liposomes. Methods Enzymol. 2005;391:330–51.
Kaur A, Jain S, Tiwary AK. Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: in vitro and in vivo evaluation. Acta Pharm. 2008;58(1):61–74.
Jain SK, Gupta Y, Jain A, Saxena AR, Khare P. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomedicine. 2008;4(1):41–8.
Dutta T, Jain NK. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly(propyleneimine) dendrimer. Biochim Biophys Acta. 2007;1770(4):681–6.
Casset F, Roux F, Mouchet P, Bes C, Chardes T, Granier C, et al. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochem Biophys Res Commun. 2003;307(1):198–205.
Zanotto C, Calderazzo F, Dettin M, Di Bello C, Autiero M, Guardiola J, et al. Minimal sequence requirements for synthetic peptides derived from the V3 loop of the human immunodeficiency virus type 1 (HIV-1) to enhance HIV-1 binding to cells and infection. Virology. 1995;206(2):807–16.
Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA. 1999;96(9):5215–20.
Yoon V, Fridkis-Hareli M, Munisamy S, Lee J, Anastasiades D, Stevceva L. The gp120 molecule of HIV-1 and its interaction with T cells. Curr Med Chem. 2010;17(8):741–9.
Hong YL, Wu LH, Cui M, McMaster G, Hunt 3rd SW, Chung FZ. New reporter cell lines to study macrophage-tropic HIV envelope protein-mediated cell–cell fusion. AIDS Res Hum Retroviruses. 1999;15(18):1667–72.
Schooley RT, Merigan TC, Gaut P, Hirsch MS, Holodniy M, Flynn T, et al. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I–II escalating dosage trial. Ann Intern Med. 1990;112(4):247–53.
ACKNOWLEDGEMENTS
This study is supported in part by NIH grants AI77390, NS39178, and RR00166, and 1UL1-RR025014 through the Institute of Translational Health Sciences.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Endsley, A.N., Ho, R.J.Y. Design and Characterization of Novel Peptide-Coated Lipid Nanoparticles for Targeting Anti-HIV Drug to CD4 Expressing Cells. AAPS J 14, 225–235 (2012). https://doi.org/10.1208/s12248-012-9329-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-012-9329-6